Deep Genomics Overview
- Founded
- 2014
- Status
- Private
- Employees
- 106
- Latest Deal Type
- Series C
- Latest Deal Amount
- $180M
- Investors
- 18
Deep Genomics General Information
Description
Operator of an AI-Powered genetic medicine discovery platform designed to interpret genetic variation. The company's AI platform uses throughput assays and advanced robotics systems to generate billions of data points and builds dozens of engineered and validated machine learning systems that support drug development, enabling researchers to classify, prioritize, interpret and link genetic variants, whether natural or therapeutic.
Contact Information
Website
www.deepgenomics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Healthcare Technology Systems
Drug Discovery
Biotechnology
Primary Office
- MaRS Centre, 661 University Avenue
- Suite 480
- Toronto, Ontario M5G 1M1
- Canada
+1 (647) 000-0000
Deep Genomics Timeline
Deep Genomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 28-Jul-2021 | $180M | 00000 | Completed | Startup | |
| 4. Later Stage VC (Series B) | 07-Jan-2020 | 0000 | 0000 | Completed | Startup | |
| 3. Early Stage VC (Series A) | 14-Aug-2017 | 0000 | 0000 | Completed | Startup | |
| 2. Seed Round | 18-Nov-2015 | $8M | $8M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Deep Genomics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of an AI-Powered genetic medicine discovery platform designed to interpret genetic variation. The company's AI
Discovery Tools (Healthcare)
Toronto, Canada
106
As of 2022
00000
00000000000
00000
00000000
rit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidata
000000000 00000 (0000000000)
Toronto, Canada
00
As of 0000
00.000
000000000
00.000
00000
ng elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
00000 0000000000 0000000000 0000000
Paris, France
000
As of 0000
00000
0.000
0000-00-00
00000000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialDeep Genomics Competitors (44)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Phenomic AI | Venture Capital-Backed | Toronto, Canada | 00 | 00.000 | 000000000 | 00.000 |
| 00000 | Venture Capital-Backed | Paris, France | 000 | 00000 | 00000000000 | 00000 |
| 000000 0000000 | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 000000000 00000000 | Venture Capital-Backed | San Diego, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 00000000 | Formerly VC-backed | Saint Sulpice, Switzerland | 000 | 00000 | 000000000 | 00000 |
Deep Genomics Patents
Deep Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210383890-A1 | Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network | Pending | 07-Jul-2021 | 000000000 | |
| CA-3128577-A1 | Ligand clusters and methods of their use and preparation | Pending | 28-Feb-2019 | 0000000000 | |
| CA-3107890-A1 | Therapeutic splice-switching oligonucleotides | Pending | 21-Aug-2018 | 0000000000 | |
| US-20200165611-A1 | Therapeutic splice-switching oligonucleotides | Pending | 21-Aug-2018 | 0000000000 | 0 |
| EP-3840758-A1 | Therapeutic splice-switching oligonucleotides | Pending | 21-Aug-2018 | C12N15/111 |
Deep Genomics Executive Team (8)
Deep Genomics Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adam D'Augelli | True Ventures | Board Member | 000 0000 |
| Alexander Morgan Ph.D | Khosla Ventures | Board Member | 000 0000 |
| Brendan Frey Ph.D | Deep Genomics | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
| Dion Madsen | Self | Board Observer | 000 0000 |
| Elena Viboch | SoftBank Investment Advisers | Board Member | 000 0000 |
Deep Genomics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialDeep Genomics Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Canada Pension Plan Investment Board | Limited Partner | Minority | 000 0000 | 000000 0 | |
| Fidelity Management & Research | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| SoftBank Investment Advisers | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| Tekla Capital Management | Asset Manager | Minority | 000 0000 | 000000 0 |